

MEDICATION REFERENCE LIST

LEVETIRACETAM (KEPPRA)

1. Classification: Anti-epileptic agent
2. Physiologic Effect: Antiepileptic mechanism unknown; may inhibit voltage-dependent N-type calcium channels; may bind to synaptic proteins that modulate neurotransmitter release; through displacement of negative modulators may facilitate GABA-ergic inhibitory transmission
3. Major Indications:
 - 3.1. adjunctive therapy in the treatment of partial onset seizures in adults and children 1 month of age and older with epilepsy
 - 3.2. adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents 12 years of age and older with juvenile myoclonic epilepsy
 - 3.3. adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in adults and children 6 years of age and older with idiopathic generalized epilepsy
 - 3.4. status epilepticus or to prevent seizures associated with subarachnoid hemorrhages (off-label use)
4. Primary Contraindications:
 - 4.1. Hypersensitivity
5. Side Effects:
 - 5.1. behavioral abnormalities and psychotic symptoms
 - 5.2. somnolence and fatigue
 - 5.3. serious dermatological reactions
 - 5.4. coordination difficulties (ataxia, abnormal gait, or incoordination)
6. Additional information: